[{"Date":"2023-02-09T00:00:00.000","Headline":"AbbVie (ABBV) Outlook Falls Short of Estimates as Humira Faces Competition","Summary":"AbbVie Inc. gave investors a first look at what profits will look like now that its $20 billion-a-year drug, Humira, faces direct competition in the US."},{"Date":"2023-02-09T00:00:00.000","Headline":"AbbVie (ABBV) Outlook Falls Short of Estimates as Humira Faces Competition","Summary":"AbbVie Inc. gave investors a first look at what profits will look like now that its $20 billion-a-year drug, Humira, faces direct competition in the US."}]